How Do We Treat Pregnancy-Related Venous Thromboembolism?
- 4 November 2019
- journal article
- review article
- Published by Georg Thieme Verlag KG in Hamostaseologie
- Vol. 40 (01) , 054-063
Abstract
Venous thromboembolism (VTE) is a major cause of maternal morbidity and mortality during pregnancy and the postpartum period. Due to a lack of adequate study data, therapeutic strategies for pregnancy-related VTE are deduced from observational studies and extrapolated from recommendations for nonpregnant patients. Because heparins do not cross the placenta, weight-adjusted therapeutic-dose low-molecular-weight heparins (LMWHs) are the anticoagulant treatment of choice in cases of VTE during pregnancy. Once- and twice-daily dosing regimens are suitable. There is no evidence that measurement of factor Xa activities and consecutive LMWH dose adjustments improve clinical outcomes. There is no support for the routine use of vitamin K antagonists, direct oral thrombin or factor Xa inhibitors, fondaparinux, or danaparoid in uncomplicated pregnancy-related VTE. Management of delivery deserves special attention, and treatment strategies depend on the time interval between the diagnosis of acute VTE and the expected delivery date. In lactating women, an overlapping switch from LMWH to warfarin is possible. Anticoagulation should be continued for at least 6 weeks postpartum or for a minimum period of 3 months.Keywords
This publication has 59 references indexed in Scilit:
- Women’s views on and adherence to low‐molecular‐weight heparin therapy during pregnancy and the puerperiumJournal of Thrombosis and Haemostasis, 2012
- Prevalence and predictors for post‐thrombotic syndrome 3 to 16 years after pregnancy‐related venous thrombosis: a population‐based, cross‐sectional, case‐control studyJournal of Thrombosis and Haemostasis, 2012
- How I treat pregnancy-related venous thromboembolismBlood, 2011
- Use of a retrievable inferior vena cava filter in term pregnancy: Case report and review of literatureAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2009
- Where do we go now with low molecular weight heparin use in obstetric care?Journal of Thrombosis and Haemostasis, 2008
- Antenatal pulmonary embolism: risk factors, management and outcomesBJOG: An International Journal of Obstetrics & Gynaecology, 2008
- The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey*British Journal of Haematology, 2007
- Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant womenThrombosis and Haemostasis, 2007
- Treatment of 51 pregnancies with danaparoid because of heparin intoleranceThrombosis and Haemostasis, 2005
- Minor Transplacental Passage of Fondaparinux in VivoNew England Journal of Medicine, 2004